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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate whether indoor residual spraying (IRS) in combination with long-lasting insecticide-treated nets (LLINs)/insecticide-
treated nets (ITNs) causes an additional reduction to malaria transmission versus LLINs/ITNs alone.
B A C K G R O U N D
Description of the condition
Although the number of malaria deaths halved globally between
2000 and 2015, there were 429,000 deaths in 2015 (WHO2016).
It is estimated that 664 million cases have been averted due to
malaria control interventions and 79% of this has been attributed
to vector control (Bhatt 2015). The 50% reduction of malaria
deaths in the past 15 years has been attributed largely to controlling
Anopheles mosquito species (Anopheles spp.) (Bhatt 2015).
Description of the intervention
Vector control depends largely on insecticides: namely in the form
of either insecticide-treated nets (ITNs) or indoor residual spray-
ing (IRS) where the insecticide is sprayed indoors on the walls
of houses (WHO 2016). ITNs include long-lasting insecticidal
nets (LLINs), where the insecticide lasts for up to three years,
and nets conventionally treated, where the insecticide is active for
up to 12 months. Currently, only pyrethroid class insecticides are
deemed safe enough to be used for LLINs/ITNs (Zaim 2000).
This restriction is not true for IRS insecticides as humans are less
likely to come into contact with the treated surface compared to
a net. IRS with dichloro-diphenyl-trichlorethane (DDT) was the
main intervention of the malaria eradication programmes in the
mid-20th century (Pluess 2010). Malaria was eliminated in many
parts of South America, Europe, and Asia and these elimination
programmes focused predominantly on IRS (Pluess 2010). De-
spite the successes of IRS, many countries today choose to adopt
LLINs/ITNs rather than IRS. This is due to LLINs/ITNs being
logistically easier to implement than IRS.
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How the intervention might work
Wewould expect an incremental effect by having a combination of
two vector control interventions, particularly two that both target
endophilic and endophagic vectors, rather than one alone. As with
many vector control interventions, the reality is not as simple
since it involves dealing with both human behaviour and vector
behaviour, which will determine the success of the intervention
(Killeen 2006). Mosquito exophily can also play a role in the
effectiveness of IRS and LLINs/ITNs as mosquitoes that tend to
rest outdoors more will have less contact with a treated wall inside
a house (Kitau 2012). Earlier biting times of Anopheles spp. have
been observed, which can reduce the impact of LLINs/ITNs as the
mosquitoes are more likely to encounter a human to bite (Ojuka
2015). Modelling data has even suggested an antagonistic effect
of combining IRS with LLINs/ITNs when LLIN/ITN coverage
is poor (Yakob 2011).
Countries that have deployed both LLINs and IRS are doing so
now as a reactive measure because of high pyrethroid resistance in
Anopheles mosquitoes. However, a combination of LLINs/ITNs
with a non-pyrethroid IRS can also be used as a proactive measure,
as part of an insecticide resistance management (IRM) strategy to
prevent pyrethroid resistance (WHO 2012). Rotating the insecti-
cide used for IRS each year could also form part of an IRM strat-
egy. However, the current World Health Organization (WHO)
guidelines for IRM are inadequate in addressing how and when
combinations and rotations of IRS with LLINs should be carried
out (WHO 2012).
Why it is important to do this review
IRS is logistically more demanding and more expensive than dis-
tributing bed nets (Kleinschmidt 2009). For example, an LLIN
typically lasts three to five years whereas the residual activity of an
insecticide on the wall lasts half a year at best with the current set
of insecticides used for IRS (WHO 2015b). Therefore an effective
spray campaign in a setting with perennial malaria transmission
would require several sprays a year. To add to this, a net distribution
campaign can be done at a community health centre, at a village
central point, and sometimes house-to-house. In contrast, carry-
ing out IRS must involve visiting every individual household. An
IRS programme takes a substantially higher amount of financial
commitment than a net distribution campaign (Goodman 2001).
Moreover, the sheer quantity of insecticide required per treatment
for IRS becomes grossly unaffordable at programmatic scales with
most non-pyrethroids even for a single application per year.
There has also been conflicting advice from theWHO.TheWHO
has recommended combinations of both LLINs/ITNs with IRS
in the past but only for epidemic situations, as stated in the Global
Technical Strategy (WHO 2015a). This contradicts the advice of
the WHO Elimination Framework which recommends that all
countries should aim to have the capacity to deploy IRS on top of
LLINs/ITNs but that the introduction of IRS should not be used
to compensate for poor coverage of LLINs/ITNs (WHO 2017).
In the past few years, combining treated nets with IRS has been a
contentious issue due to variable results from several randomized
controlled trials. As described above, spray campaigns and net dis-
tributions are organized differently. Combining the two interven-
tions would be difficult. However, it would be worthwhile if they
can achieve a greater impact than LLINs/ITNs alone. This raises
the question, in areas where the usage of LLINs/ITNs is common
practice, does IRS add additional reduction of malaria transmis-
sion?
O B J E C T I V E S
To evaluate whether indoor residual spraying (IRS) in combi-
nation with long-lasting insecticide-treated nets (LLINs)/insecti-
cide-treated nets (ITNs) causes an additional reduction to malaria
transmission versus LLINs/ITNs alone.
M E T H O D S
Criteria for considering studies for this review
Types of studies
• Randomized controlled trials (RCTs) with: (a) the unit of
randomization being a cluster and (b) at least two clusters per
arm. As the two interventions are distributed at a community
level, we do not expect to find trials with individual
randomization.
• Controlled before-and-after studies (CBAs) with: (a) a
contemporaneous control group and (b) at least two sites per
arm.
• Interrupted time series designs (ITS) with: (a) a clearly
defined point in time when the intervention occurred and (b) at
least three data points before and three after the intervention.
Types of participants
All people living in a rural or urban malarious area, all levels of
endemicity including both stable and unstable transmission.
Types of interventions
Intervention
IRS using theWorldHealthOrganization (WHO)-recommended
dosage (see Table 1) in combination with the control.
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Control
LLINs/ITNs with (a) either a full or preliminary recommendation
by the WHO or (b) a net treated with insecticide at the WHO-
recommended dose (Table 2; Table 3).
Any other malaria intervention(s) that is not IRS must be equal
in all treatment arms.
Types of outcome measures
Primary outcomes
To be eligible for inclusion, a study must report at least one of the
following primary outcomes.
• Incidence: measured as a count per person unit time of (a)
infections or (b) new infections, following treatment to avoid
measuring pre-existing infections. Infection is defined as any
symptom, including fever, with confirmed parasitaemia (by
blood smear microscopy or rapid diagnostic test (RDT)).




• Entomological Inoculation Rate (EIR): the estimated
number of bites by infectious mosquitoes per person per unit
time. This is measured using the human biting rate (the number
of mosquitoes biting an individual over a stated period measured
directly using human baits or indirectly using light traps, knock-
down catches, baited huts, or other methods of biting rate
determination) multiplied by the sporozoite rate.
• Adult mosquito density: measured by a technique
previously shown to be appropriate for the vector (measured





• Anaemia prevalence defined as per WHO cut-offs (WHO
2011).
• Hospital admissions for malaria.
• Number of people with severe disease: we will use site
specific definitions, provided they include (a) and either (b) or
(c): (a) demonstration of parasitaemia by blood smear; (b)
symptoms of cerebral malaria including coma or prostration or
multiple seizures, or both; (c) severe, life-threatening anaemia
(WHO 2015c).
• Number of people with uncomplicated clinical malaria
episodes: we will use site-specific definitions, provided they
include: (a) demonstration of malaria parasites by blood smear or
a RDT, or both; and (b) clinical symptoms including fever
detected passively or actively.
Unwanted outcome
• An increase in the level of insecticide resistance respective of
the class of insecticide used for IRS confirmed by WHO cylinder
assays/Centers for Disease Control and Prevention (CDC) bottle
bioassays/molecular techniques. This is an unwanted outcome of
trials due to increased coverage of insecticidal interventions.
Search methods for identification of studies
Wewill attempt to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We will search the following databases using the search terms
and strategy described in Appendix 1: Cochrane Infectious Dis-
eases Group Specialized Register; Central Register of Controlled
Trials (CENTRAL), published in the Cochrane Library; MED-
LINE (PubMed); Embase (OVID); and LILACS, using the
search terms detailed in Appendix 1. We will also check the
WHO International Clinical Trials Registry Platform (WHO
ICTRP; http://www.who.int/ictrp/en/) and ClinicalTrials.gov (
https://clinicaltrials.gov/ct2/home) for ongoing trials using the
terms: indoor residual spraying; IRS; insecticide-treated nets; bed-
nets; ITNs; LLIN.
Searching other resources
We will contact researchers working in the field for unpublished
data. We will also check the citations of all trials identified by the
above methods.
Data collection and analysis
Selection of studies
Two review authors (LC and JP) will independently assess the titles
and abstracts of trials identified by the searches. The same two re-
view authors will assess full-text copies of potentially relevant trials
for inclusion using an eligibility form based on inclusion criteria.
We will compare the results of our assessments and will resolve
any disagreements by discussion and consensus, with arbitration
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by a third review author (PG) if necessary. We will ensure that
multiple publications of the same trial are included once. We will
list excluded studies, together with their reasons for exclusion, in
a ‘Characteristics of excluded studies’ table. We will illustrate the
study selection process in a PRISMA diagram.
Data extraction and management
Two review authors (LC and JP) will independently extract infor-
mation from the trials using pre-piloted, electronic data extrac-
tion forms. In case of differences in extracted data, the two re-
view authors will discuss these differences to reach consensus. If
unresolved, we will consult a third review author (PG). In case
of missing data, we will contact the original study author(s) for
clarification.
We will extract data on the following.
• Trial design: type of trial; method of participant selection;
adjustment for clustering (for cluster-RCTs (cRCTs)); sample
size; method of blinding of participants and personnel.
• Participants: trial settings and population characteristics;
recruitment rates; withdrawal and loss to follow-up.
• Intervention: description of intervention and control
(active ingredient, dose, formulation, method, frequency and
timing of application, buffer zone between clusters); co-
interventions; description of control; coverage of intervention,
control, and co-interventions; compliance of intervention,
control, and any co-interventions.
• Outcomes: definition of outcome; diagnostic method or
surveillance method; passive or active case detection; duration of
follow-up; time points at which outcomes were assessed; number
of events; number of participants or unit time; statistical power;
unit of analysis; incomplete outcomes/missing data.
• Other:
◦ primary and secondary vector(s) species; vector(s)
behaviour (nature, stability, adult habitat, peak biting times, exo/
endophilic, exo/endophagic, anthro/zoophilic); method of
mosquito collection(s); phenotypic insecticide resistance (based
on WHO definitions if supplementary WHO cylinder assays or
CDC bottle bioassays, or both, were performed whilst the trial
was running); genotypic insecticide resistance profile (either
performed during the trial or if the trial references data from
previous studies done on the same local vector population within
the previous five years);
◦ malaria endemicity; eco-epidemiological setting;
population proximity and density; Plasmodium species.
For dichotomous outcomes, we will extract the number of patients
experiencing each outcome and the number of patients in each
treatment group. For count/rate data outcomes, we will extract
the number of outcomes in the treatment and control groups, and
the total person time at risk in each group or the rate ratio, and a
measure of variance (for example, standard error). For continuous
outcomes, we will extract the mean and a measure of variance
(standard deviation).
For cRCTs we will record the number of clusters randomized;
number of clusters analysed; measure of effect (such as risk ratio,
odds ratio, or mean difference) with confidence intervals (CI) or
standard deviations; number of participants; and the intracluster
correlation coefficient (ICC) value.
For non-randomized studies, we will extract adjusted measures of
intervention effects that attempt to control for confounding.
Assessment of risk of bias in included studies
Two review authors (LC and JP) will independently assess the
risk of bias for each included cRCT using the Cochrane ‘Risk of
bias’ tool and the five additional criteria listed in Section 16.3.2
of the Cochrane Handbook for Systematic Reviews of Interventions
that relate specifically to cluster-randomized trials (Higgins 2011a;
Higgins 2011b). We will assess non-randomized controlled trials
and ITS trials for risk of bias using Cochrane EPOC’s ‘Risk of bias’
tool. We will resolve any discrepancies through discussion or by
consulting a third review author (PG).We will classify judgements
of risk of bias as either at low, high, or unclear risk of bias, and
we will use summary graphs (‘Risk of bias’ summary and ‘Risk of
bias’ graph) to display results.
Measures of treatment effect
We will compare intervention and control data using risk ratios
and for count/rate data, rate ratios. We will use adjusted mea-
sures of effect to summarize treatment effect from non-random-
ized studies. We will present all results with their associated 95%
CIs.
Unit of analysis issues
For cRCTs, or cluster non-randomized trials, we will extract ad-
justed measures of effect where possible. If the study authors did
not perform any adjustment for clustering, we will adjust the raw
data ourselves using an ICC value. If an ICC is not reported in
the paper, we will obtain this from similar studies, or estimate the
ICC value. We will not present results from cluster-randomized
trials that are not adjusted for clustering. If we estimate the ICC,
we will perform sensitivity analyses to investigate the robustness
of our analyses.
If we identify studies for inclusion that have multiple intervention
arms, we will include data from these studies by either combining
treatment arms, or by splitting the control group so that we only
include these participants in the meta-analysis once.
Dealing with missing data
In case of missing data, we will apply available-case analysis, only
including data on the known results. The denominator will be
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the total number of participants who had data recorded for the
specific outcome. For outcomes with no missing data, we plan to
perform analyses on an intention-to-treat basis. We will include
all participants randomized to each group in the analyses and will
analyse participants in the group to which they were randomized.
Assessment of heterogeneity
We will inspect forest plots for overlapping CIs and will assess
statistical heterogeneity in each meta-analysis using the I² statistic
values and Chi² statistics. We will regard heterogeneity as moder-
ate if I² statistic values are between 30% to 60%; substantial if they
are between 59% to 90%; and considerable if they are between
75% to 100%. We will regard a Chi² test statistic with a P value
≤ 0.10 indicative of statistically significant heterogeneity. We will
explore clinical and methodological heterogeneity through con-
sideration of the trial populations, methods, and interventions,
and by visualization of trial results.
Assessment of reporting biases
If there are 10 or more trials included in each meta-analysis, we
will investigate reporting biases (such as publication bias) using
funnel plots. We will assess funnel plot asymmetry visually, and
use formal tests for funnel plot asymmetry (Harbord 2006). If we
detect asymmetry in any of these tests or by a visual assessment,
we will explore the reasons for asymmetry.
Data synthesis
We will analyse data using Review Manager 5 (RevMan 5)
(RevMan 2014). We will use fixed-effect meta-analysis to com-
bine data if heterogeneity is absent. If considerable heterogeneity is
present, we will combine data using random-effects meta-analysis
and report an average treatment effect. We will decide whether to
use fixed-effect or random-effects models based on the considera-
tion of clinical and methodological heterogeneity between trials,
as described previously.
Certainty of the evidence
We will assess the certainty of the evidence using the GRADE
approach (Guyatt 2011). We will rate each primary outcome as
described by Balshem 2011.
• High: we are very confident that the true effect lies close to
that of the estimate of the effect.
• Moderate: we are moderately confident in the effect
estimate. The true effect is likely to be close to the estimate of
the effect.
• Low: our confidence in the effect estimate is limited. The
true effect may be substantially different from the estimate of the
effect.
• Very low: we have very little confidence in the effect
estimate. The true effect is likely to be substantially different
from the estimate of effect.
RCTs start as high quality evidence but can be downgraded if
there are valid reasons within the following five categories: risk
of bias, imprecision, inconsistency, indirectness, and publication
bias. Studies can also be upgraded if there is a large effect; a dose
response effect; and if all plausible residual confounding would
reduce a demonstrated effect or would suggest a spurious effect if
no effect was observed (Balshem 2011). We will summarize our
findings in a ‘Summary of findings’ table.
Subgroup analysis and investigation of heterogeneity
We will explore reasons for substantial heterogeneity using sub-
group analysis. We plan to perform the following subgroup anal-
yses.
• Use of LLINs/ITNs defined by individual use from the
previous night:
◦ high (80% to 100%);
◦ moderate (50% to 79%);
◦ low (less than 50%).
• Coverage of IRS:
◦ high (80% to 100%);
◦ moderate (50% to 79%);
◦ low (less than 50%).




• Mode of action of insecticides used for IRS:
◦ voltage-gated sodium ion channels;
◦ acetylcholinesterase.
We will assess differences between subgroups using the Chi² test,
with a P value less than 0.05 indicating statistically significant
differences between subgroups.
Sensitivity analysis
Wewill perform sensitivity analysis on the primary outcome to see
the effect of exclusion of trials at high risk of bias (for allocation
concealment and incomplete outcome data) on the overall results.
If the ICC value is estimated, we will undertake sensitivity analyses
to investigate the impact of varying the ICC value onmeta-analysis
results.
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A D D I T I O N A L T A B L E S
Table 1. WHO-recommended insecticides for IRS against malaria vectors
Insecticides and formulations Dosage (g AI/m²)
DDT WP 1 to 2
Malathion WP 2
Fenitrothion WP 2
Pirimiphos-methyl WP, EC 1 to 2
Pirimiphos-methyl CS 1
Bendiocarb WP, WP-SB 0.1 to 0.4
Propoxur WP 1 to 2
Alpha-cypermethrin WP, SC, WG-SB 0.02 to 0.03
Bifenthrin WP 0.025 to 0.05
Cyfluthrin WP 0.02 to 0.05
Deltamethrin WP, WG, WG-SB, SC-PE 0.02 to 0.025
Etofenprox WP 0.1 to 0.3
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Table 1. WHO-recommended insecticides for IRS against malaria vectors (Continued)
Lambda-cyhalothrin WP, CS 0.02 to 0.03
Abbreviations: CS: capsule suspension; DDT: dichloro-diphenyl-trichlorethane; EC: emulsifiable concentrate; IRS: indoor residual
spraying; SC: suspension concentrate; SC-PE: polymer-enhanced suspension concentrate; WHO: World Health Organization;
WG: water-dispersible granule; WG-SB: water-dispersible granules packaged in water-soluble bags; WP: wettable powder; WP-SB:
wettable powder in sealed water-soluble bags.
Table 2. WHO-recommended LLINs
Product name Product type Status of WHO recommendation
DawaPlus 2.0 Deltamethrin coated on polyester Interim
Duranet Alpha-cypermethrin incorporated into polyethylene Full
Interceptor Alpha-cypermethrin coated on polyester Full
LifeNet Deltamethrin incorporated into polypropylene Interim
MAGNet Alpha-cypermethrin incorporated into polyethylene Full
MiraNet Alpha-cypermethrin incorporated into polyethylene Interim
Olyset Net Permethrin incorporated into polyethylene Full
Olyset Plus Permethrin and PBO incorporated into polyethylene Interim
Panda Net 2.0 Deltamethrin incorporated into polyethylene Interim
PermaNet 2.0 Deltamethrin coated on polyester Full
PermaNet 3.0 Combination of deltamethrin coated on polyester with
strengthened border (side panels), and deltamethrin and
PBO incorporated into polyethylene (roof )
Interim
Royal Sentry Alpha-cypermethrin incorporated into polyethylene Full
SafeNet Alpha-cypermethrin coated on polyester Full
Veeralin Alpha-cypermethrin and PBO incorporated into
polyethylene
Interim
Yahe Deltamethrin coated on polyester Interim
Yorkool Deltamethrin coated on polyester Full
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Abbreviations: LLIN: long-lasting insecticidal nets; WHO: World Health Organization.
Table 3. WHO-recommended insecticide products for treatment of mosquito nets for malaria vector control
Insecticide Formulation Dosage (mg AI/m² of netting)
Alpha-cypermethrin SC 10% 20 to 40
Cyfluthrin EW 5% 50
Deltamethrin SC 1%; WT 25%; and WT 25% + binder 15 to 25
Etofenprox EW 10% 200
Lambda-cyhalothrin CS 2.5% 10 to 15
Permethrin EC 10% 200 to 500
ICON MAXX (long-lasting lambda-cy-
halothrin formulation)
CS 10% + binder 50 to 83
Abbreviations: AI: active ingredient; EC: emulsifiable concentrate; EW: emulsion, oil in water; CS: capsule suspension; SC: suspension
concentrate; WT: water dispersible tablet; WHO: World Health Organization.
A P P E N D I C E S
Appendix 1. Search strategy
Search set Search terms
1 Malaria [ Mesh], Title/Abstract
2 Mosquito* Title/Abstract
3 “Anopheles”[Mesh]
4 1 or 2 or 3
5 “indoor residual spraying” or IRS* Title/Abstract
6 “house spray*” Title/Abstract
9The combination of indoor residual spraying with insecticide-treated nets versus insecticide-treated nets alone for preventing malaria
(Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
7 ( “Insecticides/administration and dosage”[Mesh] or “Insecticides/supply and distribution”[Mesh] or “Insecticides/
therapeutic use”[Mesh] ) or “Pyrethrins”[Mesh]
8 malathion or fenitrothion or pirimiphos-methyl or bendiocarb or propoxur or alpha-cypermethrin or bifenthrin or
cyfluthrin or deltamethrin or etofenprox or lambda-cyhalothrin or DDT Title/Abstract
9 “insecticide-treated bednet*” or insecticide-treated net*” or “Long-lasting insecticidal net*” or LLIN* or ITN* or LN*or
“bed net*”or “long-lasting net*” Title/Abstract
10 “Insecticide-Treated Bednets” [Mesh]
11 ( “Mosquito Control/instrumentation”[Mesh] OR “Mosquito Control/methods”[Mesh] )
12 5 or 6 or 7 or 8
13 9 or 10 or 11
14 4 and 12 and 13
This is the preliminary search strategy for MEDLINE (Pubmed). It will be adapted for other electronic databases. We will report all
search strategies in full in the final version of the review.
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